Professor Johann de Bono is a medical oncologist associated with The Royal Marsden NHS Foundation Trust in London, one of the UK's specialist cancer centres. His work is closely connected with cancer research, medical oncology and the development of new treatments for patients with advanced malignancies.

Professor de Bono is specifically listed among the consultants working within The Royal Marsden's Drug Development Unit (DDU). The DDU specialises in Phase I cancer drug trials, providing an important clinical environment for evaluating emerging cancer therapies and investigating new treatment approaches.

His professional field combines clinical oncology with cancer research and drug development. Early-phase clinical trials can provide patients with access to investigational treatments while generating scientific evidence about safety, tolerability, dosing and potential therapeutic activity. Such research is an important part of modern oncology, particularly for cancers where established treatment options may be limited.

At The Royal Marsden, consultants working in the Drug Development Unit collaborate with multidisciplinary teams that include specialist nurses, researchers, pharmacists, laboratory professionals and other clinical specialists. This team-based approach supports careful patient assessment and monitoring during clinical research.

Professor de Bono's association with the Drug Development Unit makes his profile particularly relevant to patients and international visitors interested in advanced cancer treatment, clinical research and investigational therapies. Patients considering clinical trials generally require an assessment of their diagnosis, previous treatments, overall clinical circumstances and eligibility for a particular research protocol.

For international patients, understanding the difference between standard cancer treatment and participation in a clinical trial is particularly important. Trial availability depends on the research protocols operating at a particular time, eligibility criteria and the patient's individual medical circumstances. A specialist oncology team can determine whether a particular study may be appropriate.

The Royal Marsden's Drug Development Unit provides a structured environment for Phase I research. The hospital's recent patient information identifies Professor Johann de Bono alongside Professor Udai Banerji, Dr Juanita Lopez, Dr Anna Minchom, Dr Adam Sharp and Dr Alec Paschalis as DDU consultants.

For patients researching oncology specialists in London, Professor Johann de Bono's profile can therefore be considered in the context of medical oncology, cancer research and early-phase drug development. His work represents the connection between specialist cancer care and research into emerging therapies.

Patients should obtain current information directly from The Royal Marsden regarding consultant availability, referral requirements, clinical-trial eligibility, treatment options and international-patient arrangements. Individual treatment decisions should be made with the patient's treating medical team after reviewing the complete clinical history.